News | EP Lab | December 10, 2018

Technology Improvements Driving Electrophysiology Market Growth

Success of device therapies over traditional pharmaceutical approaches expected to promote major market growth worldwide

Technology Improvements Driving Electrophysiology Market Growth

Navik 3D Cardiac Mapping System image courtesy of APN Health.


December 10, 2018 — Electrophysiology, while currently a relatively small market at $4.6 billion in 2018, has recently become of great interest in the medical devices field, with the market expected to reach $8.5 billion by 2023, according to GlobalData. This would represent a compound annual growth rate (CAGR) of 4.6 percent.

Interest in electrophysiology has grown as technological advancements such as live 3-D mapping and location have allowed doctors to more easily and effectively identify and ablate troublesome material. This has shortened procedure times, meaning that patients have shorter recovery times as well. This has resulted in a huge spike in growth of electrophysiology treatments at the expense of pharmacological treatments. In particular, the growth of the MEA and Latin America regions are larger at 5.6-5.7 percent year over year, due to their relatively undeveloped healthcare systems only now beginning to adopt electrophysiological technology.

James Spencer, medical devices analyst at GlobalData, commented, “Electrophysiology is uniquely positioned amongst cardiovascular devices to enjoy both explosive and sustained growth across the international markets due to a combination of as yet unsaturated markets, the cannibalization of revenue from less effective pharmacological treatments, as well as a constantly growing patient population due to the overall aging of the world’s population.”

Traditionally, electrophysiology catheters have used radiofrequency (RF) ablation techniques to ablate troublesome tissue. However, more recently, cryoablative and laser ablation technologies have been developed that are easier or more effective for physicians to use. As such, the electrophysiology market is now in a favorable position for years to come, according to GlobalData.

For more information: www.globaldata.com


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now